A single institution, open label, randomized phase 3 trial to verify the efficacy of aromatherapy tressage for Taxane-associated pain syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0005758

Enrollment

Registered

2021-01-11

Start date

2019-03-07

Completion date

Unknown

Last updated

2024-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Others : Control group will receive aromatherapy tressage at C1D2 – C1D5. At C2D1, the pain score and pain killer dosage will be checked. Questionnaire measuring quality of life will be also analyzed.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Breast cancer patients who are indicated to treat Taxane-based anticancer drugs (docetaxel, paclitaxel, nab-paclitaxel), regardless of the Adjuvant, Palliative setting. (AC followed by Docetaxel/Paclitaxel, AC followed by Docetaxel/Paclitaxel + Trastuzumab, TAC, TC, TCHP, Docetaxel/Paclitaxel monotherapy, Paclitaxel+Cisplatin, Paclitaxel+Carboplatin, Docetaxel+Epirubicin, Paclitaxel+Ifosfamide) 2. Patients receiving Taxane-based anticancer drugs for the first time in their lives 3. Over 20 years old 4. Those who have agreed to the explanation and consent form 5. Those who can fill out a questionnaire and can express pain through VAS score 6. A person who can fill out a questionnaire in Korean according to the standards. 7. Those who are willing to comply with the research plan and to comply with the treatment plan during the study period.

Exclusion criteria

Exclusion criteria: 1. Patients with known side effects of Taxane-based anticancer drugs. 2. Patients who have previously been given Taxane-based anticancer drugs. 3. Patients with extensive bone metastases. 4. Patients with severe musculoskeletal disorders or peripheral vascular disease, as judged by the researcher 5. Those who are taking anticoagulant or antiplatelet drugs. 6. Those who are currently receiving massage care. 7. History of major surgery or severe trauma within 28 days of study start. 8. Substance abusers who are judged to interfere with research participation and interpretation of research results 9. Those with medical/psychiatric/social diseases. 10. At the discretion of the researcher, patients who have a medical condition that may increase the risk due to participation in the study, or interfere with the interpretation of test results, or who have abnormal laboratory test values.

Countries

Korea, Republic of

Contacts

Public ContactJuwon Kim

Korea University Anam Hospital

kohyot35@gmail.com+82-2-920-6287

Outcome results